Efficacy and safety of oral beclomethasone dipropionate and budesonide MMX 5-aminosalicylates or placebo in ulcerative colitis: a systematic review and meta-analysis [PDF]
Therapeutic Advances in Gastroenterology, 2023 Background: Low bioavailability steroids, including beclomethasone dipropionate (BDP) and budesonide MMX, have been developed to ensure colonic targeting and low systemic activity than systematic corticosteroids in treating patients with ulcerative ...
Brigida Barberio +8 more
doaj +4 more sources
Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety [PDF]
Therapeutics and Clinical Risk Management, 2021 Giovanni Maconi, Deborah Camatta, Rosanna Cannatelli, Francesca Ferretti, Anna Carvalhas Gabrielli, Sandro Ardizzone Gastroenterology Unit, Department of Biomedical and Clinical Sciences FBF – L.Sacco, University Hospital, Milan ...
Maconi G +5 more
doaj +4 more sources
The Egyptian Journal of Internal MedicineBackground Recently licensed to treat mild or moderate ulcerative colitis (UC), Budesonide MMX is a corticosteroid of the second generation designed to distribute pharmacologically active drugs throughout the colon.
Mohammed A Medhat
exaly +3 more sources
MMX® technology and its applications in gastrointestinal diseases [PDF]
Therapeutic Advances in Gastroenterology, 2017 The Multimatrix ® (MMX ® ) preparation MMX ® is a recently obtained drug formulation developed to facilitate release of high concentrations of active drugs into the colon, with a homogeneous distribution along all colonic segments, particularly the most ...
Luca Pastorelli +2 more
exaly +3 more sources
Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis. [PDF]
Journal of Crohn's and Colitis, 2015 BACKGROUND AND AIMS: Cumulative safety and tolerability of budesonide MMX(®), a once-daily oral corticosteroid for inducing mild to moderate ulcerative colitis remission, was examined. METHODS: Data from three randomized, double-blind, placebo-controlled,
Silvio Danese, Simon Travis
exaly +3 more sources
Use, effectiveness and tolerability of budesonide-MMX in ulcerative colitis: A real-life experience [PDF]
United European Gastroenterology Journal, 2019 Background: Budesonide-MMX has an established role in the management of relapsing mild-to-moderate ulcerative colitis. Data regarding effectiveness and tolerability in real-life clinical practice are limited.
Nicolò Mezzina +2 more
exaly +4 more sources
Comparative Outcomes of Budesonide MMX versus Prednisolone for Ulcerative Colitis: Results from a British Retrospective Multi-Centre Real-World Study [PDF]
Journal of Clinical Medicine, 2021 During the COVID-19 pandemic many IBD units chose Budesonide MMX (Cortiment) as the first-line treatment for flares of ulcerative colitis (UC) in outpatients for its favourable side effect profile. This retrospective study of all UC patients treated with
Richard C Pollok +2 more
exaly +4 more sources
Increased failure of budesonide MMX for ulcerative colitis during the COVID-19 pandemic: a population-based study [PDF]
Therapeutic Advances in GastroenterologyBackground: Corticosteroids induce remission in ulcerative colitis (UC) but are associated with adverse effects, including prednisone ⩾20 mg/day associated with serious COVID-19 outcomes.
Stephanie Coward +10 more
doaj +2 more sources
Assessment of the effectiveness of Budesonide MMX® for active, mild-to-moderate ulcerative colitis in the Polish sub-group of the CORE Practice prospective multi-centre observational study [PDF]
Gastroenterology Review, 2023 Maciej Jesionowski +3 more
doaj +2 more sources
Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis [PDF]
British Journal of Clinical Pharmacology, 2019 Stefanos Bonovas +2 more
exaly +2 more sources